


[illegible]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<div style="text-align: center;">  </div>	
<div style="text-align: center;"> <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i> </div>				<i>Complete if Known</i>	
				Application Number	10/716,975
				Filing Date	November 19, 2003
				First Named Inventor	Ekwuribe, Nnochiri N., et al.
				Art Unit	1651
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	014811-29.8DV3

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. <b>9233. 8DV3</b> <del>4012-113</del>		SERIAL NO. <b>To be assigned</b> <del>09/134,803</del>	
INFORMATION DISCLOSURE STATEMENT  (use several sheets if necessary)				APPLICANT Nnochiri N. Ekwuribe			
				FILING DATE <b>Concurrently herewith</b> August 14, 1998		GROUP <del>1646</del> <b>1651</b>	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<div style="font-size: 2em; font-weight: bold;">176</div>	AA	4,585,754	29 Apr. 1986	Meisner et al.			
	AB	4,179,337	18 Dec. 1979	Davis et al.			
	AC	4,003,792	18 Jan. 1977	Mills et al.			
	AD	4,849,405	18 Jul. 1989	Ecanow			
	AE	5,013,556	7 May 1991	Woodle et al.			
	AF	4,963,367	16 Oct. 1990	Ecanow			
	AG	4,044,196	23 Aug. 1977	Hüper et al.			
	AH	4,717,566	5 Jan. 1988	Eckenhoff et al.			
	AI	4,698,264	6 Oct. 1987	Steinke			
	AJ	4,684,524	4 Aug. 1987	Eckenhoff et al.			
	AK	4,410,547	18 Oct. 1983	Ueno et al.			
	AL	3,256,153	14 Jun. 1966	Heimlich			
	AM	4,935,246	19 Jun. 1990	Ahrens			
	AN	4,797,288	10 Jan 1989	Sharma et al.			
	AO	4,744,976	17 May 1988	Snipes et al.			
	AP	5,055,304	8 Oct. 1991	Makino et al.			
	AQ	5,055,300	8 Oct. 1991	Gupta			
	AR	4,772,471	20 Sep. 1988	Vanlerberghe et al.			
	AS	5,093,198	3 Mar. 1992	Speaker et al.			
	AT	4,840,799	20 Jun. 1989	Appelgren et al.			
AU	4,622,392	11 Nov. 1986	Hong et al.				
AV	5,653,987	5 Aug. 1997	Modi et al.				
AW	5,792,834	11 Aug. 1998	Hakimi et al.				
AX	5,595,732	21 Jan. 1997	Hakimi et al.				
AY	5,539,063	23 Jul. 1996	Hakimi et al.				
Continue on page 2							
EXAMINER <i>176 tomen</i>						DATE CONSIDERED <i>11/4/04</i>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. <del>4012-113</del> <b>9233.8DV3</b>		SERIAL NO. <b>To be assigned</b> <del>09/134,803</del>	
INFORMATION DISCLOSURE STATEMENT  (use several sheets if necessary)				APPLICANT Nnochiri N. Ekwuribe			
				FILING DATE <b>Concurrently herewith</b> <del>August 14, 1998</del>		GROUP <del>1646</del> <b>1651</b>	
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>RG</i>	AZ	5,559,213	24 Sep 1996	Hakimi et al.			
	BA	5,747,646	5 May 1998	Hakimi et al.			
	BB	5,286,637	15 Feb. 1994	Veronese et al.			
	BC	5,631,263	20 May 1997	Portoghese et al.			
	BD	5,602,099	11 Feb. 1997	Schiller			
	BE	5,545,719	13 Aug. 1996	Shashoua et al.			
	BF	5,641,861	24 Jun. 1997	Dooley et al.			
	BG	5,663,295	2 Sep. 1997	Moreau et al.			
	BH	5,786,447	28 Jul. 1998	Schiller et al.			
	BI	4,939,174	3 Jul. 1990	Shashoua			
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	BJ	WO93/01802	PCT/Switzerland				X
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	BK	Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res., 1991, 8 (12): pp. 1453-1459.					
	BL	Boccu, E. et al., "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase," Pharm. Res. Comm., 1982, 14: pp. 11-120.					
	BM	Igarashi, R. et al., "Biologically Active Peptides Conjugated with Lecithin for DDS" Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater. 1990, 17: pp. 367-368.					
	BN	Taniguchi, T. et al., "Synthesis of Acyloyl Lysozyme and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats," Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater., 1992, 19: pp. 104-105.					
	BO	Russell-Jones, G. J., "Vitamin B12 Drug Delivery," Proceed. Intern. Symp. Control. Rel. Bioactive. Mater., 1992, 19: pp. 102-103.					
	BP	Baudys, M. et al., "Synthesis and Characteristics of Different Glycosylated Derivatives of Insulin," Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater., 1992, 19: pp. 210-211.					
	BQ	Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcell Deffer, Inc., New York, NY, 1992.					
Continued on page 3							
EXAMINER <i>RG</i>						DATE CONSIDERED <i>11/4/04</i>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4012-113 <b>9233.8DV3</b>	SERIAL NO. <b>To be assigned</b> 09/134,803
INFORMATION DISCLOSURE STATEMENT  (use several sheets if necessary)			APPLICANT Nnochiri N. Ekwuribe	
			FILING DATE <b>Concurrently herewith</b> August 14, 1998	GROUP <del>1646</del> <b>1651</b>
BR	Pardridge, W.M., "CNS Drug Design Based on Principles of Blood-Brain Barrier Transport," J. Neurochem., 1998, 70 (5): pp. 1781-1792.			
BS	Kroll, R.A., et al., "Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means," 1998 Neurosurgery, 42 (5): pp. 1083-1100.			
BT	Pardridge, W.M., "Blood-Brain Barrier Peptide Transport and Peptide Drug Delivery to the Brain," Amer. Chem Soc. 1995, pp: 265-296.			
BU	Banks, W.A., et al., "Passage of Peptides Across the Blood-Brain Barrier: Pathophysiological Perspectives," Life Sciences, 1996, 59 (23), pp: 1923-1943.			
BV	Fix, J.A., "Oral Controlled Release Technology for Peptides: Status and Future Prospects," Pharm. Res., 1996, 13 (12): pp: 1760-1763.			
BW	Terasaki, T., et al., "Oligopeptide Drug Delivery to the Brain," Amer. Chem. Soc. 1995, pp: 297-316.			
BX	Bodor, N., et al., "Molecular Packaging. Peptide Delivery to the Central Nervous System by Sequential Metabolism," Amer. Chem. Soc., 1995, p:317-337.			
BY	Nestor, J., "Improved Duration of Action of Peptide Drugs," Amer. Chem Soc. 1995, pp:449-471.			
BZ	Santiago, N. et al., "Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres," Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater., 1992, 19: pp. 116-117.			
CA	Banting, R. G., et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," The Canadian Med. Assoc. J. 1922, 12: pp. 141-146.			
CB	Brange, J. et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): pp. 715-726.			
CC	Nucci, et al., "The Therapeutic Value of Poly(ethylene glycol) - Modified Proteins," Ac. Drug. Del. Rev. 1991, 6: pp. 133-151.			
CD	Brange, J. et al., "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): pp. 727-734.			
CE	Robbins, D. C. et al., "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients," Diabetes, 1987, 36: pp. 838-841.			
CF	Maislos, M. et al., "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin," J. Clin. Invest., 1986, 77: pp. 717-723.			
CG	Ratner, R. E. et al., "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates," Diabetes, 1990, 39: pp. 728-733.			
CH	Oka, K. et al., "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation," Pharm. Res., 1990, 7 (8): pp. 852-855.			
CI	Saffran, M. et al., "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science, 1986, 233: pp. 1081-1084.			
CJ	Abuchowski, A. and F. F. Davis, "Soluble Polymer-Enzyme Adducts," pp. 368-383, Enzymes as Drugs, J. S. Holcenberg, John Wiley, 1981.			
CK	Akiyama, M. et al., "The Synthesis of New Derivatives of 1-β-D-Arabinofuranosylcytosine," Chem. Pharm. Bull., 1978, 26(3): p. 981.			
CL	Gish, D. T. et al., "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-β-D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity," J. Med. Chem., 1971, 14(12): pp. 1159-1162.			
Continue on Page 4				
EXAMINER <i>R. Gutman</i>			DATE CONSIDERED <i>11/4/04</i>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				

FORM PTO-1449 US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. <del>4012-113</del> 9233.8DV3	SERIAL NO. To be assigned <del>09/134,803</del>
INFORMATION DISCLOSURE STATEMENT  (use several sheets if necessary)		APPLICANT  Nnochiri N. Ekwuribe	
		FILING DATE Concurrently herewith <del>August 14, 1998</del>	GROUP  1646- 1651
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)			
CM	Baker, D. C. et al., "Prodrugs of 9-β-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(O-Acyl) Derivatives," J. Med. Chem., 1978, 21(12): pp. 1218-1221.		
CN	Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," The Journal of Biological Chemistry, 1990, 265(11): pp. 6112-6117.		
CO	Hong, C. I. et al., "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids," J. Med. Chem., 1986, 29: pp. 2038-2044.		
CP	Aoshima, M. et al., "N <sup>4</sup> -Behenoyl-1-β-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent," Cancer Research, 1977, 37: pp. 2481-2486.		
CQ	Zalipsky, S. et al., "Attachment of Drugs to Polyethylene Glycols," Eur. Polym. J., 1983, 19(12): pp. 1177-1183.		
CR	Tsuzuki, N., et al., "Rapid Communication. Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug: Antinociceptive Effects of [D-Ala <sup>2</sup> ] Leu-Enkephalin Derivatives Conjugated with the 1-Adamantane Moiety," Biochemical Pharmacology, 1991, 41 (4): pp. R5-R8.		
CS	Wagner, J., et al., "Neuropharmacology of Endogenous Opioid Peptides," Psychopharmacology: The Fourth Generation of Progress, 1995, pp: 519-529.		
CT	Horvat, J., et al., "Synthesis and Biological Activity of [Leu <sup>5</sup> ] Enkephalin Derivatives Containing D-Glucose," J. Peptide Protein Res., 1988, 31, pp: 499-507.		
CU	Shashoua V.E., et al., "γ-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of γ-Aminobutyric Acid," J. Med. Chem., 1984, 27 (5), pp: 660-664.		
CV	Brewster, M., et al., "Tissue Distribution of LY231617, an Antioxidant with Neuroprotectant Activity, in the Rat," J. Pharm. Studies, 1995, 84 (7), pp: 791-793.		
CW	Chen, C., et al., "Extensive Biliary Excretion of the Model Opioid Peptide [D-PEN <sup>2,3</sup> ] Enkephalin in Rats," Pharm. Res. J., 14, pp: 345-350.		
CX	Bodor, N., et al., "A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism," Science, 1992, 257, pp: 1698-1702.		
CY	Sim, L., et al., "In vitro Autoradiography of Receptor-Activated G Proteins in Rat Brain by Agonist-stimulated Guanylyl 5'-[γ <sup>35</sup> S]thio]-Triphosphate Binding," Proc. Natl. Acad. Sci., USA, 1995, 92, pp: 7242-7246.		
CZ	Weber, S.J., et al., "Whole Body and Brain Distribution of [ <sup>3</sup> H]Cyclic [D-PEN <sup>2</sup> , D-PEN <sup>3</sup> ] Enkephalin after Intraperitoneal, Intravenous, Oral and Subcutaneous Administration," J. Pharm. Exper. Ther., 1992, 263 pp: 1308-1316.		
DA	Alyautdin, R.N., "Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles," Pharm. Res. J., 1997, 14, pp: 325-328.		
DB	Chiou, G.C.Y., et al., "Systemic Delivery of Enkephalin Peptide through Eyes," Life Sciences, 1988, 43, pp: 509-514.		
DC	Sakaeda, T., et al., "Conjugation with L-Glutamic Acid for Brain Drug Delivery," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 1966, 23, pp: 607-608.		
Continue on Page 5			
EXAMINER  R. G. Tamen		DATE CONSIDERED  11/4/04	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. #012-113 <b>9233.80V3</b>		SERIAL NO. <b>To be assigned</b> 09/134,803	
INFORMATION DISCLOSURE STATEMENT  (use several sheets if necessary)				APPLICANT  Nnochiri N. Ekwuribe			
				FILING DATE <b>Concurrently herewith</b> August 14, 1998		GROUP  1646 / 651	
	DD	Chun, W., et al., "Transmucosal Delivery of Methionine Enkephalin. I: Solution Stability and Kinetics of Degradation in Various Rabbit Mucosa Extracts," J. Pharm.Sci., 1993, 82 (4), pp: 373-378.					
	DE	Brewster, M.E., et al., "Efficacy of a 3-Substituted Versus 17-Substituted Chemical Delivery System for Estradiol Brain Targeting," J. Pharm. Sci., 1994, pp: A-E.					
	DF	Mosnaim, A.D., et al., "Studies of the in Vitro Human Plasma Degradation of Methionine-Enkephalin," Gen. Pharmac., 1988, 19 (5), pp: 729-733.					
	DG	Weber, S.J., et al., "Distribution and Analgesia of [ <sup>3</sup> H][D-PEN <sup>2</sup> , D-PEN <sup>3</sup> ] Enkephalin and Two Halogenated Analogs after Intravenous Administration," J. Pharm. Exper. Ther., 1991, 259, pp: 1109-1112.					
	DH	Brewster, M.E., et al., "Effect of Molecular Manipulation on the Estrogenic Activity of a Brain-Targeting Estradiol Chemical Delivery System," J. Med. Chem., 1994, 37, pp: 4237-4244					
	DI	Pardridge, W.M., "New Approaches to Drug Delivery Through the Blood-Brain Barrier," Trends in Biotechnology, 1994, pp: 239-245.					
	DJ	Shashoua, V.E., et al., "N-Docosahexaenoyl, 3 Hydroxytyramine: A Dopaminergic Compound that Penetrates the Blood-Brain Barrier and Suppresses Appetite," Life Sciences, 58 (16), pp: 1347-1354.					
	DK	Gibson, A.M., et al., "Specificity of Action of Human Brain Alanyl Aminopeptidase on Leu-Enkephalin and Dynorphin-Related Peptides," Neuropeptides, 1989, 13, pp: 259-262.					
	DL	Prokai-Tatrai, K., et al., "Brain-Targeted Delivery of a Leucine-Enkephalin Analogue by Retrometabolic Design," J. Med. Chem, 1996, 39 (24).					
Continue on Page							
EXAMINER <i>R610MEL</i>				DATE CONSIDERED <i>11/4/04</i>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

[illegible]



[illegible]

